<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856984</url>
  </required_header>
  <id_info>
    <org_study_id>GN ZIKA</org_study_id>
    <nct_id>NCT02856984</nct_id>
  </id_info>
  <brief_title>Zika in Infants and Pregnancy (ZIP)</brief_title>
  <official_title>International Prospective Observational Cohort Study of Zika in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RTI International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this multisite, multicountry Zika in Infants and Pregnancy (ZIP)
      study is to assess the strength of the association between Zika virus infection (ZIKV) during
      pregnancy and adverse maternal/fetal outcomes and the risk of vertical transmission. The
      study will prospectively enroll a cohort of pregnant women during the first trimester of
      pregnancy and follow them through their pregnancy to identify for clinical evidence of acute
      ZIKV, while controlling for potential confounders. Outcomes in the women, the developing
      fetus, and infants will be assessed. All protocol-specified data will be recorded and entered
      in a central data management system for the purposes of analysis of composite data from the
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this multisite, multicountry Zika in Infants and Pregnancy (ZIP)
      study is to assess the strength of the association between Zika virus infection (ZIKV) during
      pregnancy and adverse maternal/fetal outcomes and the risk of vertical transmission. The
      study will prospectively enroll a cohort of pregnant women during the first trimester of
      pregnancy and follow them through their pregnancy to identify for clinical evidence of acute
      ZIKV, while controlling for potential confounders. Outcomes in the women, the developing
      fetus, and infants will be assessed. All protocol-specified data will be recorded and entered
      in a central data management system for the purposes of analysis of composite data from the
      study.

      The study will recruit 10,000 pregnant women in their first trimester from ZIKV-endemic
      regions and follow them longitudinally to study the impact of incident ZIKV during pregnancy
      on maternal, fetal, and newborn outcomes. Researchers will identify cases of incident ZIKV
      among pregnant women by monitoring for symptoms of Zika-like illness and performing serial
      laboratory sampling for diagnosis of seroconversion and viral shedding. After delivery,
      infants born with evidence of ZIKV or born to mothers diagnosed with incident virus infection
      will be followed in a prospective longitudinal cohort for at least 1 year. In addition, a
      control group of infants born to mothers without evidence of ZIKV during pregnancy will be
      followed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV infected participants</measure>
    <time_frame>Time of birth of infant</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV infected participants</measure>
    <time_frame>3 months of age</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV infected participants</measure>
    <time_frame>6 months of age</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV infected participants</measure>
    <time_frame>12 months of age</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV infected participants</measure>
    <time_frame>Time of birth of infant</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, central nervous system (CNS) malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV infected participants</measure>
    <time_frame>3 months of age</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, central nervous system (CNS) malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV infected participants</measure>
    <time_frame>6 months of age</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, central nervous system (CNS) malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV infected participants</measure>
    <time_frame>12 months of age</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, central nervous system (CNS) malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV symptomatic participants</measure>
    <time_frame>Time of birth of infant</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV symptomatic participants</measure>
    <time_frame>3 months of age</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV symptomatic participants</measure>
    <time_frame>6 months of age</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of congenital malformations for ZIKV symptomatic participants</measure>
    <time_frame>12 months of age</time_frame>
    <description>To measure the incidence of congenital malformations in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV symptomatic participants</measure>
    <time_frame>Time of birth of infant</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, CNS malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV symptomatic participants</measure>
    <time_frame>3 months of age</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, CNS malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV symptomatic participants</measure>
    <time_frame>6 months of age</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, CNS malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse fetal outcomes for ZIKV symptomatic participants</measure>
    <time_frame>12 months of age</time_frame>
    <description>To measure the incidence of adverse fetal outcomes (including microcephaly, fetal demise, neonatal death, CNS malformations, hydrops, and ocular abnormalities) in fetuses/infants.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Zika Virus Disease (Disorder)</condition>
  <arm_group>
    <arm_group_label>ZIKV infected women</arm_group_label>
    <description>The study will prospectively enroll pregnant women during the first trimester of pregnancy and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women in the first trimester will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (uninfected women)</arm_group_label>
    <description>The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      maternal samples from urine, blood, genital secretions, saliva, and breast milk, and when
      available amniotic fluid and tissue; infant urine, blood, and saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit 10,000 pregnant women in their first trimester from ZIKV-endemic
        regions and follow them longitudinally to study the impact of incident ZIKV during
        pregnancy on maternal, fetal, and newborn outcomes. Researchers will identify cases of
        incident ZIKV among pregnant women by monitoring for symptoms of Zika-like illness and
        performing serial laboratory sampling for diagnosis of seroconversion and viral shedding.
        After delivery, infants born with evidence of ZIKV or born to mothers diagnosed with
        incident virus infection will be followed in a prospective longitudinal cohort for at least
        1 year. In addition, a control group of infants born to mothers without evidence of ZIKV
        during pregnancy will be followed.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age &gt;15 years

          -  Assent and consent as required per local country regulations

          -  Confirmation of pregnancy by beta human chorionic gonadotropin (hCG) measurement in
             blood/urine or ultrasound confirmation of pregnancy with fetal heart tones present

          -  Confirmation of being within first trimester of pregnancy (between 4-12 weeks) based
             on pregnancy calculator or fetal ultrasound

        Exclusion Criteria: Pregnant Women

          -  Women who cannot adhere to proposed testing schedule

          -  Pregnant women enrolled in other research including other ZIKV research

        Inclusion Criteria (newborn)

          -  All infants born to women enrolled in the observational cohort are eligible for
             enrollment

        Exclusion Criteria (newborn)

          -  Mother or custodial parent does not consent to have child participate

          -  Infants born to mothers that are not part of the ZIP cohort study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Ximenes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Britt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama Birmingham School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marisa Mussi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ribeirão Preto Medical School, University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Ko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University, Laboratory of Epidemiology and Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deolinda Scalabrin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marisa Elisabeth Lopes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Fernandes Figueira - FIOCRUZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Garces, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Cordero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Milagros Velez Vega</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Puerto Rico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Seage, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard University School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Zorilla</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Puerto Rico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Harris</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Californina Berkeley</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel Balmaseda</last_name>
    <role>Principal Investigator</role>
    <affiliation>MINSA Central</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Osorio</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Dario Velez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth M McClure, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nahida Chakhtoura,, MD</last_name>
    <phone>(301) 435-6872</phone>
    <email>nahida.chakhtoura@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walla Dempsey, PhD</last_name>
    <phone>(240) 292-4197</phone>
    <email>WDEMPSEY@niaid.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS; Rue Waldemar Falcao</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40296-710</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deolinda Scalabrin</last_name>
      <email>deolindascalabrin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <zip>CEP: 50670-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Ximenes, MD</last_name>
      <email>raaximenes@uol.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Fernandes Figueira - FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22250-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria E Lopes</last_name>
      <email>bebeth@iff.fiocruz.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - Monte Alegre</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa M Mussi, MD</last_name>
      <email>mmmpinha@fmrp.usp.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidad de Antioquia</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Dario Velez</last_name>
      <email>id_velez@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP)</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Garces, MD</last_name>
      <email>agarces@incap.int</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MINSA Central</name>
      <address>
        <city>Managua</city>
        <zip>16064</zip>
        <country>Nicaragua</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Balmaseda</last_name>
      <email>abalmaseda@minsa.gob.ni</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Milagros Velez Vega</last_name>
      <email>carmen.velez2@upr.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico - Recinto de Río Piedras</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Zorilla</last_name>
      <email>carmen.zorrilla@upr.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Guatemala</country>
    <country>Nicaragua</country>
    <country>Puerto Rico</country>
  </location_countries>
  <reference>
    <citation>WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations; 1 February 2016. Available at http://www.who.int/ mediacentre/news/statements/2016/1st-emergency-committee-zika/en/</citation>
  </reference>
  <reference>
    <citation>CDC. Chikungunya virus. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/chikungunya/hc/clinicalevaluation.html</citation>
  </reference>
  <reference>
    <citation>CDC Zika Virus; Areas with Zika http://www.cdc.gov/zika/geo/index.html</citation>
  </reference>
  <reference>
    <citation>CDC. West Nile virus: insect repellent use &amp; safety. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/westnile/faq/repellent.html.</citation>
  </reference>
  <reference>
    <citation>CDC. Zika virus. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/zika/index.html</citation>
  </reference>
  <reference>
    <citation>http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Informes %20Arbovirales/Reporte%20ArboV%20semana%204-2016.pdf</citation>
  </reference>
  <reference>
    <citation>Julie A Boom; Microcephaly in infants and children: Etiology and evaluation UpToDate http://www.uptodate.com/contents/microcephaly-in-infants-and-children- etiology-and-evaluation?source=machineLearning&amp;search=microcephaly+in +pregnacy&amp;selectedTitle=2~130§ionRank=3&amp;anchor=H55603463#H55603463 Accessed on February 16, 2016</citation>
  </reference>
  <reference>
    <citation>Medscape Medical News; FDA Issues Guidance to Protect Blood Supply From Zika Virus http://www.medscape.com/viewarticle/858976? nlid=100283_3901&amp;src=wnl_newsalrt_160216_MSCPEDIT&amp;uac=17333MK&amp;impID=993653&amp;faf=1</citation>
  </reference>
  <results_reference>
    <citation>Petersen EE, Staples JE, Meaney-Delman D, Fischer M, Ellington SR, Callaghan WM, Jamieson DJ. Interim Guidelines for Pregnant Women During a Zika Virus Outbreak--United States, 2016. MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):30-3. doi: 10.15585/mmwr.mm6502e1.</citation>
    <PMID>26796813</PMID>
  </results_reference>
  <results_reference>
    <citation>Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, Gordon-Smith E, Milliken S, Tiley C. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet. 1990 Dec 8;336(8728):1417-20.</citation>
    <PMID>1978880</PMID>
  </results_reference>
  <results_reference>
    <citation>Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva: World Health Organization; 2009.</citation>
    <PMID>23762963</PMID>
  </results_reference>
  <results_reference>
    <citation>Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? Ultrasound Obstet Gynecol. 2016 Jan;47(1):6-7. doi: 10.1002/uog.15831.</citation>
    <PMID>26731034</PMID>
  </results_reference>
  <results_reference>
    <citation>Oduyebo T, Petersen EE, Rasmussen SA, Mead PS, Meaney-Delman D, Renquist CM, Ellington SR, Fischer M, Staples JE, Powers AM, Villanueva J, Galang RR, Dieke A, Muñoz JL, Honein MA, Jamieson DJ. Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure - United States, 2016. MMWR Morb Mortal Wkly Rep. 2016 Feb 12;65(5):122-7. doi: 10.15585/mmwr.mm6505e2.</citation>
    <PMID>26866840</PMID>
  </results_reference>
  <results_reference>
    <citation>Babaliche P, Doshi D. Catching Dengue Early: Clinical Features and Laboratory Markers of Dengue Virus Infection. J Assoc Physicians India. 2015 May;63(5):38-41.</citation>
    <PMID>26591143</PMID>
  </results_reference>
  <results_reference>
    <citation>Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011 Dec;3(12):2374-95. doi: 10.3390/v3122374. Epub 2011 Nov 25. Review.</citation>
    <PMID>22355444</PMID>
  </results_reference>
  <results_reference>
    <citation>Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ, Fischer M, Staples JE. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg. 2012 Dec;87(6):1112-5. doi: 10.4269/ajtmh.2012.12-0182. Epub 2012 Oct 29.</citation>
    <PMID>23109371</PMID>
  </results_reference>
  <results_reference>
    <citation>Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003 Mar;9(3):376-9.</citation>
    <PMID>12643836</PMID>
  </results_reference>
  <results_reference>
    <citation>Chervenak FA, Jeanty P, Cantraine F, Chitkara U, Venus I, Berkowitz RL, Hobbins JC. The diagnosis of fetal microcephaly. Am J Obstet Gynecol. 1984 Jul 1;149(5):512-7.</citation>
    <PMID>6742021</PMID>
  </results_reference>
  <results_reference>
    <citation>Chervenak FA, Rosenberg J, Brightman RC, Chitkara U, Jeanty P. A prospective study of the accuracy of ultrasound in predicting fetal microcephaly. Obstet Gynecol. 1987 Jun;69(6):908-10.</citation>
    <PMID>3554067</PMID>
  </results_reference>
  <results_reference>
    <citation>Kurtz AB, Wapner RJ, Rubin CS, Cole-Beuglet C, Ross RD, Goldberg BB. Ultrasound criteria for in utero diagnosis of microcephaly. J Clin Ultrasound. 1980 Feb;8(1):11-6.</citation>
    <PMID>6766470</PMID>
  </results_reference>
  <results_reference>
    <citation>Hutchon DJ. Fetal ultrasound biometry: 1. Head reference values. Br J Obstet Gynaecol. 1999 Aug;106(8):875-6.</citation>
    <PMID>10453845</PMID>
  </results_reference>
  <results_reference>
    <citation>Berger I. Prenatal microcephaly: can we be more accurate? J Child Neurol. 2009 Jan;24(1):97-100. doi: 10.1177/0883073808321045.</citation>
    <PMID>19168823</PMID>
  </results_reference>
  <results_reference>
    <citation>Tolmie JL, McNay M, Stephenson JB, Doyle D, Connor JM. Microcephaly: genetic counselling and antenatal diagnosis after the birth of an affected child. Am J Med Genet. 1987 Jul;27(3):583-94.</citation>
    <PMID>3307411</PMID>
  </results_reference>
  <results_reference>
    <citation>Atkinson B, Hearn P, Afrough B, Lumley S, Carter D, Aarons EJ, Simpson AJ, Brooks TJ, Hewson R. Detection of Zika Virus in Semen. Emerg Infect Dis. 2016 May;22(5):940. doi: 10.3201/eid2205.160107.</citation>
    <PMID>27088817</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarno M, Sacramento GA, Khouri R, do Rosário MS, Costa F, Archanjo G, Santos LA, Nery N Jr, Vasilakis N, Ko AI, de Almeida AR. Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise. PLoS Negl Trop Dis. 2016 Feb 25;10(2):e0004517. doi: 10.1371/journal.pntd.0004517. eCollection 2016 Feb.</citation>
    <PMID>26914330</PMID>
  </results_reference>
  <results_reference>
    <citation>Brasil P, Pereira JP Jr, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, Rabello RS, Valderramos SG, Halai UA, Salles TS, Zin AA, Horovitz D, Daltro P, Boechat M, Raja Gabaglia C, Carvalho de Sequeira P, Pilotto JH, Medialdea-Carrera R, Cotrim da Cunha D, Abreu de Carvalho LM, Pone M, Machado Siqueira A, Calvet GA, Rodrigues Baião AE, Neves ES, Nassar de Carvalho PR, Hasue RH, Marschik PB, Einspieler C, Janzen C, Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N Engl J Med. 2016 Dec 15;375(24):2321-2334. Epub 2016 Mar 4.</citation>
    <PMID>26943629</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>de-identified participant data will be entered into the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (N-DASH) system.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

